布地格福吸入气雾剂对慢阻肺的治疗效果观察  

Observation on the Therapeutic Effect of Budesonide Inhalation Aerosol on Chronic Obstructive Pulmonary Disease

作　　者：冯青青[1] 高崴崴 刘待见[1] FENG Qingqing;GAO Weiwei;LIU Daijian(Department of Respiratory and Critical Care Medicine,The Second Affiliated Hospital of Zhengzhou University,Zhengzhou Henan 450014,China)

机构地区：[1]郑州大学第二附属医院呼吸与危重症医学科,河南郑州450014

出　　处：《临床研究》2024年第8期96-99,共4页Clinical Research

摘　　要：目的观察慢阻肺(COPD)患者开展布地格福吸入气雾剂的治疗效果。方法研究对象为郑州大学第二附属医院2021年7月至2023年7月收治的72例COPD患者,经随机抽签法分为参照组(采用布地奈德治疗)与干预组(采用布地格福治疗),各36例。对比分析两组治疗效果。结果两组治疗前临床指标相比差异统计学意义(P>0.05);治疗后干预组动脉血二氧化碳分压(PaCO_(2))、呼吸与心率频次均低于参照组,动脉血氧分压(PaO_(2))高于参照组,差异有统计学意义(P<0.05);两组治疗前肺功能指标相比差异无统计学意义(P>0.05);治疗后干预组呼气峰值流速(PEF)、第1秒用力呼气容积(FEV_(1))、用力肺活量(FVC)、第1秒用力呼气容积/用力肺活量(FEV_(1)/FVC)、肺活量(VC)指标均高于参照组,差异有统计学意义(P<0.05);两组治疗前炎性指标相比差异无统计学意义(P>0.05);干预组治疗后血清淀粉样蛋白A(SAA)、C反应蛋白(CRP)水平均低于参照组,差异有统计学意义(P<0.05);两组治疗前生活质量问卷(QOL-I)与医学研究会呼吸困难量表(MRC)评分相比差异无统计学意义(P>0.05);干预组治疗后QOL-I评分高于参照组,MRC评分低于参照组,差异有统计学意义(P<0.05)。结论COPD患者经布地格福吸入气雾剂治疗效果显著,能够在改善血氧与肺功能的同时,改善机体炎症反应,改善呼吸困难与生活质量,值得临床应用。Objective To observe the therapeutic effect of Budesonide inhalation aerosol on patients with chronic obstructive pulmonary disease(COPD).Methods The research subjects were 72 patients with COPD treated in The Second Affiliated Hospital of Zhengzhou University from July 2021 to July 2023.They were divided into a reference group(treated with Budesonide)and an intervention group(treated with Budesonide inhalation aerosol)by random drawing,with 36 cases in each group.The therapeutic effects of the two groups were compared and analyzed.Results Before treatment,there was no statistical significance in the comparison of clinical indicators between the two groups(P>0.05).After treatment,the arterial carbon dioxide tension(PaCO_(2))and the frequency of respiration and heart rate in the intervention group were lower than those in the reference group,and the arterial partial pressure of oxygen(PaO_(2))was higher than that in the reference group,with statistically significant differences(P<0.05).Before treatment,there was no statistical significance in the comparison of lung function indicators between the two groups(P>0.05).After treatment,the peak expiratory flow rate(PEF),forced expiratory volume in the first second(FEV_(1)),forced vital capacity(FVC),FEV_(1)/FVC,and vital capacity(VC)indicators of the intervention group were all higher than those of the reference group,with statistically significant differences(P<0.05).Before treatment,there was no statistical significance in the comparison of inflammatory indicators between the two groups(P>0.05).After treatment,the levels of serum amyloid A(SAA)and C-reactive protein(CRP)in the intervention group were lower than those in the reference group,with statistically significant differences(P<0.05).Before treatment,there was no statistical significance in the comparison of the Quality of Life Inventory(QOL-I)and Medical Research Council Dyspnea Scale(MRC)scores between the two groups(P>0.05).After treatment,the QOL-I score of the intervention group was higher than that of the

关 键 词：阻塞性肺疾病 炎症指标 肺功能 布地格福 生活质量 

分 类 号：R563[医药卫生—呼吸系统]